Recent Updates
Recently added Catalysts
ENGN Positive Sentiment

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: enGene Therapeutics Inc. will host a virtual key opinion leader event on August 11, 2026, focusing on the non-muscle invasive bladder cancer (NMIBC) market. Dr. Neal Shore will provide insights into the treatment landscape, showcasing the company's commitment to advancing genetic medicine. This event aims to enhance understanding of NMIBC considerations.

Market Sentiment Analysis

POSITIVE FACTORS

  • enGene is actively engaging with KOLs to discuss NMIBC market insights.
  • The event highlights the evolving treatment landscape for NMIBC.
  • Featuring a reputable expert, Dr. Neal Shore, adds credibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~23 mo
Low dilution risk
Lead asset
EG-70
Phase 2 · Superficial Bladder Cancer

Full Press Release Details

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research Center; Atlantic Urology Clinics). Dr. Shore will join management to provide insights into the evolving NMIBC treatment landscape and the various considerations dr

Frequently Asked Questions

What is the date of enGene's virtual KOL event?

The virtual KOL event will take place on August 11, 2026.

Who will speak at the enGene KOL event?

Dr. Neal Shore will speak at the event, providing insights on NMIBC.

What is the focus of the KOL event?

The event will focus on the evolving treatment landscape for NMIBC.

What time will the event start?

The event is scheduled to start at 11:00 AM ET.

ShareAdd on Google
Tags: ENGN Viatris Investor Conferences Healthcare enGene NMIBC Neal Shore genetic medicine clinical-stage
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$258M liquidity · $11M/mo burn
~23 mo
Low dilution risk
Lead asset
EG-70Phase 2
Superficial Bladder Cancer →